ICOS and non-small cell lung carcinoma: Rochigneux P reported that inducible T-cell co-stimulator (ICOS)+ CD4+ T cells were closely associated with better survival for patients receiving pembrolizumab in NSCLC (Rochigneux et al., 2022).